{"prompt": "['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', '94']['2016N293064 0', 'CONFIDENTIAL', '2018N394263_00', 'GlaxoSmithKline group of companies', '205864', 'TITLE PAGE', 'Protocol Title: A randomized, double-blind, Sponsor open, placebo-controlled, 52 week', 'study evaluating the effect of danirixin (GSK1325756) on lung function and health', 'related quality of life in participants with mild to moderate Chronic Obstructive', 'Pulmonary Disease (COPD).', 'Protocol Number: 205864', 'Short Title: Danirixin Pilot Study for Disease Progression in COPD', 'Compound Number: GSK1325756', 'Sponsor Name and Legal Registered Address:', 'GlaxoSmithKline Research & Development Limited', '980 Great West Road', 'Brentford', 'Middlesex, TW8 9GS', 'UK', 'Medical Monitor Name and Contact Information will be provided in the Study', 'Reference Manual', 'Regulatory Agency Identifying Number(s): IND: 108168', 'Approval Date: 21-MAR-2017', 'Copyright 2017 the GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorised copying or use of this information is prohibited.', '1']['2018N394263_00', '2016N293064_00', 'CONFIDENTIAL', '-', '205864', 'SPONSOR SIGNATORY:', 'PPD', '21-Mar-2017', 'Aili L. Lazaar, MD', 'PPD', 'Date', 'Clinical Development Director,', 'Respiratory Therapy Area Unit', 'PPD', '2']\n\n###\n\n", "completion": "END"}